Structured reference

Duloxetine

Antidepressants · Oral delayed-release capsule

Reference information · Structured reference
Last content update
2026-10-27
Clinical review
Not independently reviewed
Source jurisdiction
See individual sources
Coverage
Structured reference
What changed in this edition

Clinical essentials #

Reference fieldScope
Formulation / routeOral delayed-release capsule
Selected adult indicationMajor depressive disorder in adults
MechanismSerotonin and noradrenaline reuptake inhibition.

Indications & formulation #

Major depressive disorder in adults. This reference covers the selected formulation; other indications and products need their own evidence.

Dose reference #

Adult educational reference · Oral delayed-release capsule · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.

Selected starting range is 40–60 mg/day; 30 mg/day for one week may improve tolerability before 60 mg/day. Doses above 60 mg/day showed no additional average MDD benefit.

Contraindications & important cautions #

Avoid MAOIs. Significant alcohol exposure or chronic liver disease increases concern for hepatic injury.

Selected important cautions; consult the full product information for all contraindications and warnings.

Adverse effects #

Nausea, sweating, blood-pressure effects and discontinuation symptoms; hepatic concerns require attention.

Interactions #

Review serotonergic drugs, CYP1A2/CYP2D6 interactions, alcohol exposure and hepatic/renal restrictions.

Monitoring #

Assess blood pressure, liver-related history, renal context, activation and the intended psychiatric or pain indication.

Special populations #

Avoid in chronic liver disease/cirrhosis and severe renal impairment (GFR below 30 mL/min). Older GAD patients have a different initiation schedule.

Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.

Discontinuation, restarting & counseling #

Taper; monitor dizziness, sensory symptoms, anxiety and recurrence.

Brands & products #

Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.

Reference coverage #

Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.

References · 1
  1. Duloxetine — Oral delayed-release capsule — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral delayed-release capsule · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling

Keep MindEven close.

In Chrome or Edge, open your browser menu and look for Install or Add to home screen.

On iPhone or iPad, open this website in Safari, tap Share, then Add to Home Screen. Availability depends on your browser.

MindEven uses the same website pages and requires an internet connection.

Mira

MindEven’s AI reference assistant

Connecting…

What would you like to understand?

Explore an idea, compare concepts or find a source.